{"id":70156,"date":"2026-07-17T19:02:18","date_gmt":"2026-07-17T11:02:18","guid":{"rendered":"https:\/\/flcube.com\/?p=70156"},"modified":"2026-07-17T19:02:19","modified_gmt":"2026-07-17T11:02:19","slug":"jasper-therapeutics-completes-acquisition-of-kira-pharmaceuticals-in-all-stock-transaction-secures-132m-private-placement-for-complement-therapies-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70156","title":{"rendered":"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jasper Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/JSPR:NASDAQ\">NASDAQ: JSPR<\/a>) announced the completion of its acquisition of <strong>Kira Pharmaceuticals<\/strong> through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol &#8220;JSPR&#8221; and has simultaneously secured a $132 million private placement financing to advance Kira&#8217;s complement therapies pipeline for immune-mediated diseases.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquisition Type<\/strong><\/td><td>All-stock transaction<\/td><\/tr><tr><td><strong>Target Company<\/strong><\/td><td>Kira Pharmaceuticals<\/td><\/tr><tr><td><strong>Ticker Symbol<\/strong><\/td><td>JSPR (unchanged)<\/td><\/tr><tr><td><strong>Financing<\/strong><\/td><td>$132 million private placement<\/td><\/tr><tr><td><strong>Shares Issued<\/strong><\/td><td>4.7 million shares of non-voting convertible preferred stock<\/td><\/tr><tr><td><strong>Closing Date<\/strong><\/td><td>Expected July 20, 2026<\/td><\/tr><tr><td><strong>Conversion Terms<\/strong><\/td><td>Each preferred share converts to 61 common shares upon stockholder approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-investor-consortium\" class=\"wp-block-heading\">Investor Consortium<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Investors:<\/strong> Affinity Asset Advisors, LLC and Ikarian Capital LLC<\/li>\n\n\n\n<li><strong>Participating Institutions:<\/strong> Columbia Threadneedle Investments, Sirenia Capital Management LP, Brahma Capital, Balyasny Asset Management, SilverArc Capital, Squadron Capital Management, Nazare Partners LP, Mirador Therapeutics<\/li>\n\n\n\n<li><strong>Additional Participants:<\/strong> Certain members of Kira&#8217;s management team<\/li>\n\n\n\n<li><strong>Strategic Alignment:<\/strong> Strong backing from leading life sciences investors with expertise in immunology and rare disease therapeutics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-kira-pharmaceuticals-pipeline-overview\" class=\"wp-block-heading\">Kira Pharmaceuticals Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Stage<\/th><th>Mechanism<\/th><th>Key Indications<\/th><\/tr><\/thead><tbody><tr><td><strong>KP-104 (Vensobafusp alfa)<\/strong><\/td><td>Clinical<\/td><td>First-in-class dual-target complement therapeutic<\/td><td>IgA nephropathy, C3 glomerulopathy, SLE-TMA, PNH<\/td><\/tr><tr><td><strong>Briquilimab<\/strong><\/td><td>Late-stage<\/td><td>Anti-KIT antibody with best-in-class potential<\/td><td>Immune-mediated disorders<\/td><\/tr><tr><td><strong>KP-701<\/strong><\/td><td>Preclinical<\/td><td>B-cell receptor targeting therapy<\/td><td>Autoimmune conditions<\/td><\/tr><tr><td><strong>Out-licensed Assets<\/strong><\/td><td>\u2014<\/td><td>KP-301 (anti-C5a mAb), KP-402 (C5aR antagonist)<\/td><td>Licensed to Mirador Therapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Focus:<\/strong> Immune-mediated diseases represent a $150+ billion global market with significant unmet medical needs<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Kira&#8217;s complement-focused pipeline complements Jasper&#8217;s existing hematopoietic cell transplant platform<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> KP-104&#8217;s dual-target mechanism offers potential advantages over single-target complement inhibitors currently on the market<\/li>\n\n\n\n<li><strong>Financial Position:<\/strong> The $132 million financing provides runway through multiple Phase III readouts and potential commercial launch preparations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complement Inhibition Market:<\/strong> Currently dominated by Alexion&#8217;s Soliris and Ultomiris, with emerging competition from Apellis and others<\/li>\n\n\n\n<li><strong>KP-104 Advantage:<\/strong> Dual-target approach may address limitations of current anti-C5 therapies in specific patient populations<\/li>\n\n\n\n<li><strong>Market Timing:<\/strong> Increasing regulatory acceptance of complement-targeted therapies creates favorable environment for pipeline advancement<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition, financing, clinical development timelines, and market opportunities. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, integration challenges, and competitive dynamics in the biopharmaceutical industry.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4861,3339,4862,24],"class_list":["post-70156","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-jasper-therapeutics","tag-kira-pharmaceuticals","tag-nasdaq-jspr","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol &quot;JSPR&quot; and has simultaneously secured a $132 million private placement financing to advance Kira&#039;s complement therapies pipeline for immune-mediated diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70156\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline\" \/>\n<meta property=\"og:description\" content=\"Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol &quot;JSPR&quot; and has simultaneously secured a $132 million private placement financing to advance Kira&#039;s complement therapies pipeline for immune-mediated diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70156\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T11:02:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T11:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70156#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70156\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline\",\"datePublished\":\"2026-07-17T11:02:18+00:00\",\"dateModified\":\"2026-07-17T11:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70156\"},\"wordCount\":390,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Jasper Therapeutics\",\"Kira Pharmaceuticals\",\"NASDAQ: JSPR\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70156#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70156\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70156\",\"name\":\"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-17T11:02:18+00:00\",\"dateModified\":\"2026-07-17T11:02:19+00:00\",\"description\":\"Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol \\\"JSPR\\\" and has simultaneously secured a $132 million private placement financing to advance Kira's complement therapies pipeline for immune-mediated diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70156#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70156\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70156#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol \"JSPR\" and has simultaneously secured a $132 million private placement financing to advance Kira's complement therapies pipeline for immune-mediated diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70156","og_locale":"en_US","og_type":"article","og_title":"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline","og_description":"Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol \"JSPR\" and has simultaneously secured a $132 million private placement financing to advance Kira's complement therapies pipeline for immune-mediated diseases.","og_url":"https:\/\/flcube.com\/?p=70156","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-17T11:02:18+00:00","article_modified_time":"2026-07-17T11:02:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70156#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70156"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline","datePublished":"2026-07-17T11:02:18+00:00","dateModified":"2026-07-17T11:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70156"},"wordCount":390,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Jasper Therapeutics","Kira Pharmaceuticals","NASDAQ: JSPR","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70156#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70156","url":"https:\/\/flcube.com\/?p=70156","name":"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-17T11:02:18+00:00","dateModified":"2026-07-17T11:02:19+00:00","description":"Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol \"JSPR\" and has simultaneously secured a $132 million private placement financing to advance Kira's complement therapies pipeline for immune-mediated diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70156#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70156"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70156#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70156"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70156\/revisions"}],"predecessor-version":[{"id":70157,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70156\/revisions\/70157"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}